Science Creates opens second incubator, including Imophoron as one of the most exciting deep tech company.6 December 2021Science Creates, the deep tech ecosystem that nurtures science and engineering start-ups and spin-outs, has opened its second specialised incubator space in Bristol on Thursday 25 November 2021. It will be home to a new generation of scientists-turned-entrepreneurs leveraging advanced technologies such as AI, synthetic biology, nano technologies and quantum computing which will be used to tackle big problems such as cancer, vaccine development and climate change.
Collaborative COVID-19 lockdown effort delivers major boost for vaccine innovation in Bristol7 October 2021Faster vaccine development could be a step closer thanks to £4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer™. Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya.
Statue of Henrietta Lacks unveiled at University of Bristol5 October 2021A life-size bronze statue of Henrietta Lacks, a Black American woman whose cells were the first ever to survive and multiply outside the body, and whose use changed the course of modern medicine, has been unveiled at the University of Bristol by members of her family to honour the 70th anniversary of her cells first being used.
How Bristol’s research has played a key role in the world’s response to COVID-1923 March 2021As the COVID-19 pandemic hit the world, academics from across the University of Bristol joined together to understand the virus and the impact of the pandemic. Today [23 March] is a year since the first UK lockdown and their research is continuing to play a key role in global efforts to overcome the disease.
How vitamins, steroids and potential antivirals might affect SARS-CoV-228 January 2021Evidence is emerging that vitamin D – and possibly vitamins K and A – might help combat COVID-19. A new study from the University of Bristol published in the journal of the German Chemical Society Angewandte Chemie has shown how they – and other antiviral drugs – might work. The research indicates that these dietary supplements and compounds could bind to the viral spike protein and so might reduce SARS-CoV-2 infectivity. In contrast, cholesterol may increase infectivity, which could explain why having high cholesterol is considered a risk factor for serious disease.